Desarrollamos terapias génicas innovadoras para enfermedades neurodegenerativas mediante un mecanismo de acción multifuncional
Equipo científico integrado por investigadores con más de 30 años de experiencia en neurociencia
Investigación
Desarrollamos terapias génicas innovadoras para enfermedades neurodegenerativas mediante un mecanismo de acción multifactorial
Portfolio
Enforque radicalmente nuevo con un gran impacto sobre enfemedades neurodegenerativas
Equipo científico
Equipo científico integrado por investigadores con más de 30 años de experiencia en neurociencia
Con sede en Madrid y Valencia, Tetraneuron nace como spin-off del Instituto Cajal, perteneciente al Consejo Superior de Investigaciones Científicas (CSIC)
2023
Nuevas alianzas estratégica en párkinson y envejecimiento
2022
Reunión pre-IND con la FDA
2021
Inicio de la fase preclínica regulatoria
2020
Validación de la ruta de administración
2019
Estudios de eficacia y caracterización del perfil ADME-Tox en modelos murinos de EA
2018
Optimización del compuesto principal
2017
Validación del compuesto principal
2016
Identificación del compuesto principal
2015
Validación del target terapéutico E2F4
2014
Comienzo de la prueba de concepto
2013
Identificación del target terapéutico E2F4
2012
Se funda Tetraneuron
Desarrollamos terapias génicas para enfermedades neurodegenerativas. Estas terapias están diseñadas para restaurar los procesos biológicos que han sido afectados por la fosforilación patogénica de E2F4.
Terapia génica basada en E2F4DN. Un enfoque prometedor para la enfermedad de Alzheimer.
Método para determinar de forma temprana el riesgo de desarrollar la enfermedad de Alzheimer.
Presentamos un enfoque radicalmente innovador que promete impacto transformador en la salud cerebral.
E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging (2022)
A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice (2022)
E2F4 as a single multifactorial target against Alzheimer’s disease (2021)
El equipo científico cuenta con personal con más de 30 años de experiencia en neurociencia y ejecutivos de empresas biofarmacéuticas como socios.
Miembro del Comité Científico
Miembro del Comité Científico
Director Científico y Co-Fundador
Directora Gerente
Directora de I+D
Directora Técnica
Consejero
Investigadora Senior
Investigadora
Técnico de Laboratorio
Técnico de Laboratorio
Asesora Estratégica
Asesor Estratégico
Asesor Estratégico
Estudiante de Doctorado
TETRANEURON
Check out our participation in the launch of #ComunidadDesafia! 🚀
We’re excited to be part of this dynamic community and look forward to the opportunities and collaborations ahead.
TETRANEURON
We had the privilege of attending the EMEA Summit as part of the JLabs family. 🌍✨
Johnson & Johnson Innovation – JLABS is a global life science network offering startups like ours access to expertise, a vibrant community, essential industry connections, and comprehensive entrepreneurial programs.
Being a part of this dynamic network accelerates our mission and amplifies our impact in the life sciences sector.💡🧬
TETRANEURON
Yesterday, we had an inspiring partner meeting at TETRANEURON , reaffirming our commitment to pioneering innovative gene therapies for neurodegenerative diseases. We extend our gratitude to our partners for their ongoing support. Together, we are making a difference!🚀 #GeneTherapy #NeurodegenerativeDiseases #Innovation#Tetraneuron
TETRANEURON
🚀 Exciting News! 🚀 We’re thrilled to announce that we’ll be attending the RESI Europe conference in Barcelona on June 19th! Our team is excited to present our innovative project to international investors. Let’s connect and explore opportunities at RESI Europe. See you in Barcelona! 🤝 #RESIEurope #Barcelona #Innovation #Investment #Networking
TETRANEURON
https://www.linkedin.com/posts/tetraneuron_tetraneuron-genetherapy-activity-7183463740216885248-vUp3
TETRANEURON
Embracing Change in 2024: We’re giving our website a fresh new look! Join us on this exciting journey to stay in the loop with all things Tetraneuron. Don’t miss out on the latest from Tetraneuron 🚀 https://tetraneuron.com #TetraneuronUpdates #genetherapy
TETRANEURON
Last week, we had a really interesting session with our SAB Member Alvaro Pascual-Leone. Definitely, we have a lot of promising options to explore for our therapy now. Big thanks to Alvaro for sharing his talent with us! #genetherapy #Alzheimer #innovation #braindiseases
TETRANEURON
🎉🌟 BIG NEWS! 🌟🎉🏢🌟 We’re proud to announce a major milestone for TETRANEURON ! Our new corporate headquarters in Madrid is officially open, marking a significant step in our journey. 🎉 . This dynamic space, in the heart of Madrid, has been designed to inspire collaboration, innovation, and growth towards developing life-changing gene therapies for neurodegenerative diseases. Join us on this incredible path at our stunning location: 📍 C/Velázquez 154, Madrid. ✨ We can’t wait to welcome you to our new space! 💫 #Tetraneuron #genetherapy #innovation #bignews
TETRANEURON
Fascinating piece by Expansión discussing the power of patents in companies like TETRANEURON . We’re all about robust IP for every innovation we craft🚀 Thank you, Alive comunicación! 🌟 #patents #genetherapy
TETRANEURON
We were delighted to have the opportunity to speak at #Biozell‘s #InvestorDay. Such events are pivotal in highlighting the innovation within the Spanish biotech sector. It was a pleasure to share the stage with other remarkable projects! #bioval #tetraneuron #alzheimer #genetherapy
TETRANEURON
Excited to welcome amazing investors like Biozell! 🚀 Mark your calendar for October 17th. During the Investor’s Day, they will present their ongoing ventures and brand-new investment possibilities. We’re thrilled to showcase our project at this event. Don’t miss this opportunity to join it! #investment #alzheimer #genetherapy
TETRANEURON
Great day at #BioRNConference, Next-Generation Cell and Gene Therapies. #genetherapy #alzheimer
TETRANEURON
It was a pleasure attending the event «CERCO AL ALZHEIMER» at the Universidad Europea of Madrid. Our Scientific Advisor, Teodoro Del Ser Quijano, led an engaging discussion on therapeutic advancements and their current status. A remarkable event during the #Alzheimer‘s month 2023 #Alzheiemer #genetherapy
TETRANEURON
Meet us at #BIOSPAIN2023 in Barcelona ! Just a few days left to interact with experts, companies and investors from all over the world. Find our colleagues Maria del Mar Municio, Ph.D and M.Carmen Alvarez Abril at the partnering area. See you there! #Alzheimer #genetherapy
TETRANEURON
Exciting News! Join us at #IBRO2023 Conference. Our colleagues Cristina Sánchez-Puelles, PhD and Morgan Ramón Landreau will be presenting our amazing research on Alzheimer’s Disease. Visit us! 📌Poster B28 📌Poster B03 #genetherapy #Tetraneuron #alzheimer
TETRANEURON
Great news! Congratulations to Maria del Mar Municio, Ph.D for her incorporation as R&D Director at TETRANEURON .Undoubtedly, her experience and leadership will further drive the innovation and development of the company. #Tetraneuron #Innovation #Leadership #alzheimer #genetherapy
TETRANEURON
Delighted by the industry’s progress! 👏 Yet, Alzheimer’s Drug Discovery Foundation reminds us to explore diverse pathways for more effective treatments. Our promising therapy targets key areas to make a difference. #Alzheimers #genetherapy #Tetraneuron
TETRANEURON
Muchas gracias #Valenciaplaza por haceros eco de esta importante noticia para #Tetraneuron Estamos encantados de contar con #Biozellventures como nuevo socio y contar con el enorme talento y experiencia de Angela Perez y su equipo. ¡Seguimos! 🚀🚀🚀🚀🚀 #genetherapy #alzheimersdisease #advancedtherapies #parkinson #biotech
TETRANEURON
Muchas gracias #Mendelbrain por haceros eco de esta importante noticia para #Tetraneuron ¡Seguimos! #terapiagenica #genetherapy #cns #snc #alzheimers #parkinson #aging #innovation #biotech #advancedtherapies
TETRANEURON
Great news!🚀 Biozell Ventures, the investment arm of BIOHUB VLC, is betting on Tetraneuron’s new gene therapy for Alzheimer’s disease. Please join us in welcoming our newest investors to the Tetraneuron family! #alzheimer #genetherapy
TETRANEURON
The Alzheimer’s Association®International Conference (AAIC)- the most relevant conference on #alzheimer– starts next Sunday, 16 July, in Amsterdam! The Tetraneuron team is looking forward to joining researchers and clinicians to discuss the latest advances in the field. Several team members will present a poster during the event! – José María Frade. Scientific Director – Cristina Sánchez-Puelles, PhD. Senior Researcher – Morgan Ramón Landreau. Researcher Visit our posters or meet the team to learn more about our therapy TET-101. See you in #AAIC2023! #Tetraneuron #alzheimer #genetherapy
Te invitamos a sumarte a este nuevo camino de las enfermedades neurodegenerativas
Un nuevo camino para las enfermedades neurodegenerativas
Contacto
VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia
MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid
VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia
MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid
VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia
MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid